Medherant Raises £3 Million for Innovative Testosterone Patch
Medherant, an innovative biotechnology company situated in Coventry, UK, has successfully raised £3 million in funding to further develop its groundbreaking testosterone patch aimed at alleviating menopausal symptoms in women. The investment was spearheaded by Mercia Asset Management, a company known for identifying and supporting high-potential growth firms. This infusion of capital will play a crucial role in scaling Medherant's operations and enhancing its research initiatives as it seeks to bring its product to market.
Under the leadership of CEO John Burt, Medherant is focused on the development of a testosterone replacement patch tailored for women experiencing menopausal symptoms.
This pioneering product utilizes a proprietary adhesive technology that has been meticulously crafted by the company’s scientists. The design of the patch ensures that it delivers the precise dosage of testosterone necessary for effective treatment, requiring users to change it just twice a week. This convenience, combined with the therapeutic benefits, positions Medherant to address a significant need in the healthcare market.
The founders of Medherant have ambitious plans for the company as it moves forward. The next critical steps involve initiating clinical trials later this year, with the goal of obtaining regulatory approval in the UK and beyond. This regulatory approval is vital for the company, as it will pave the way for commercializing the testosterone patch and making it available to women who could greatly benefit from this treatment. As the company progresses, the guidance and support from Mercia Asset Management will undoubtedly aid Medherant in navigating the complex landscape of biotech product development and regulatory compliance.
They've invested in Medherant
Get to know these Biotech investors
Click here for a full list of 7,526+ startup investors in the UK